India, Aug. 18 -- Soligenix, Inc. (SNGX) surged 92.15 percent to $5.34, up $2.56 on Monday, after announcing that the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behcet's Disease. The decision follows encouraging Phase 2a trial results showing biological efficacy and safety in patients. The stock opened at $3.79 and traded between $3.57 and $6.23, with volume spiking to 169.53 million shares, far above its average of 8.06 million on the Nasdaq. Soligenix's 52-week range is between $1.09 and $6.23.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....